OhioHealth Riverside Methodist Hospital

Sorting 6 by

Not yet accepting

DREAMM-10

A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
  • Antibody Drug Conjugate (ADC)
  • BCMA
  • Phase 3

Accepting patients

MajesTEC-7

A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)
  • Bispecific Antibody
  • BCMA
  • Randomization
  • Phase 3
  • Has results

Not currently accepting

Belantamab Mafodotin Combination Therapy

A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination With Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma
  • Antibody Drug Conjugate (ADC)
  • BCMA
  • Phase 1/2

Accepting patients

MagnetisMM-7

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7)
  • Bispecific Antibody
  • GPRC5D
  • Phase 3

Accepting patients

EQUATE

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
  • Monoclonal Antibody
  • CD38
  • Phase 3

Not currently accepting

Early Detection Blood Tests

Blinded Reference Set for Multicancer Early Detection Blood Tests
  • Observational Trial